Literature DB >> 19958947

Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid?

Jack M Monchik1, Caroline J Simon, Diana L Caragacianu, Alan A Thomay, Vicki Tsai, Jonah Cohen, Peter J Mazzaglia.   

Abstract

BACKGROUND: There is controversy regarding the need for prophylactic level VI central node dissection in patients with low-risk papillary thyroid carcinoma (PTC). This study focuses on the incidence of persistent level VI nodal disease in low-risk PTC without prophylactic central node dissection.
METHODS: PTC was known at the time of thyroidectomy in 304 of the 761 patients who had initial thyroid surgery from 2001 to 2007. Therapeutic level VI node dissection was performed for suspicious or positive nodes. A prophylactic central node dissection was not done if suspicious nodes were not identified. All patients had a high-resolution ultrasonography, and almost all patients had a suppressed serum thyroglobulin level 4-6 months after thyroidectomy.
RESULTS: A total of 112 of 304 patients (37%) had a therapeutic level VI node dissection. A prophylactic central node dissection was not performed in the remaining 192 patients. One hundred and sixty-one of the 192 patients (84%) were low risk. Biopsy-proven persistent disease was identified at the 4-6-month postoperative ultrasonography in only 3 of the 161 low-risk patients (1.8%). The suppressed serum thyroglobulin level was increased in these 3 patients and 2 additional patients.
CONCLUSION: Failure to perform a prophylactic central node dissection in low-risk PTC resulted in both a very low incidence of persistent level VI nodal disease and elevated suppressed thyroglobulin 4-6 months after thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958947     DOI: 10.1016/j.surg.2009.10.024

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection.

Authors:  I J Nixon; L Y Wang; I Ganly; S G Patel; L G Morris; J C Migliacci; R M Tuttle; J P Shah; A R Shaha
Journal:  Br J Surg       Date:  2015-10-29       Impact factor: 6.939

2.  Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.

Authors:  Don Yoo; Saad Ajmal; Shilpa Gowda; Jason Machan; Jack Monchik; Peter Mazzaglia
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 3.  Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes.

Authors:  P Asimakopoulos; I J Nixon; A R Shaha
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-01-13       Impact factor: 4.126

4.  Intraoperative ultrasonography is useful in surgical management of neck metastases in differentiated thyroid cancers.

Authors:  Burak Ertas; Hakan Kaya; Neslihan Kurtulmus; Abdullah Yakupoglu; Serdar Giray; Omer Faruk Unal; Mete Duren
Journal:  Endocrine       Date:  2014-05-27       Impact factor: 3.633

5.  Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.

Authors:  Ashok R Shaha
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

6.  Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases.

Authors:  Alexandre Bozec; Olivier Dassonville; Emmanuel Chamorey; Gilles Poissonnet; Anne Sudaka; Isabelle Peyrottes; Francette Ettore; Juliette Haudebourg; Françoise Bussière; Danielle Benisvy; Pierre-Yves Marcy; Jean Louis Sadoul; Paul Hofman; Sandra Lassale; Jacques Vallicioni; François Demard; José Santini
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-24       Impact factor: 2.503

7.  Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Naoyoshi Onoda; Hitoshi Noguchi; Akira Yoshida
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

8.  Value of ultrasound in detecting central compartment lymph node metastases in differentiated thyroid carcinoma.

Authors:  Aviram Mizrachi; Raphael Feinmesser; Gideon Bachar; Ohad Hilly; Maya Cohen
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-24       Impact factor: 2.503

Review 9.  Management of the Neck in Well-Differentiated Thyroid Cancer.

Authors:  Panagiotis Asimakopoulos; Ashok R Shaha; Iain J Nixon; Jatin P Shah; Gregory W Randolph; Peter Angelos; Mark E Zafereo; Luiz P Kowalski; Dana M Hartl; Kerry D Olsen; Juan P Rodrigo; Vincent Vander Poorten; Antti A Mäkitie; Alvaro Sanabria; Carlos Suárez; Miquel Quer; Francisco J Civantos; K Thomas Robbins; Orlando Guntinas-Lichius; Marc Hamoir; Alessandra Rinaldo; Alfio Ferlito
Journal:  Curr Oncol Rep       Date:  2020-11-14       Impact factor: 5.075

10.  Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients.

Authors:  Alexander Rehders; Martin Anlauf; Ilona Adamowsky; Markus H Ghadimi; Sarah Klein; Christina Antke; Kenko Cupisti; Nikolas H Stoecklein; Wolfram T Knoefel
Journal:  Pathol Oncol Res       Date:  2013-08-06       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.